Hanako Kobayashi
Last active: 10/27/2014

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. Kapitsinou PP, Sano H, Michael M, Kobayashi H, Davidoff O, Bian A, Yao B, Zhang MZ, Harris RC, Duffy KJ, Erickson-Miller CL, Sutton TA, Haase VH (2014) J Clin Invest 124(6): 2396-409
    › Primary publication · 24789906 (PubMed) · PMC4092875 (PubMed Central)
  2. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. Kobayashi H, Gilbert V, Liu Q, Kapitsinou PP, Unger TL, Rha J, Rivella S, Schlöndorff D, Haase VH (2012) J Immunol 188(10): 5106-15
    › Primary publication · 22490864 (PubMed) · PMC3345098 (PubMed Central)
  3. Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. Kobayashi H, Huang J, Ye F, Shyr Y, Blackwell TS, Lin PC (2010) PLoS One 5(3): e9458
    › Primary publication · 20221440 (PubMed) · PMC2832764 (PubMed Central)
  4. Interleukin-32 positively regulates radiation-induced vascular inflammation. Kobayashi H, Yazlovitskaya EM, Lin PC (2009) Int J Radiat Oncol Biol Phys 74(5): 1573-9
    › Primary publication · 19616744 (PubMed) · PMC2713876 (PubMed Central)
  5. Molecular characterization of IL-32 in human endothelial cells. Kobayashi H, Lin PC (2009) Cytokine 46(3): 351-8
    › Primary publication · 19364659 (PubMed) · PMC2704890 (PubMed Central)
  6. Angiogenesis links chronic inflammation with cancer. Kobayashi H, Lin PC (2009) Methods Mol Biol : 185-91
    › Primary publication · 19347298 (PubMed)
  7. Nanotechnology for antiangiogenic cancer therapy. Kobayashi H, Lin PC (2006) Nanomedicine (Lond) 1(1): 17-22
    › Primary publication · 17716205 (PubMed)
  8. Endothelial cell adhesion molecules and cancer progression. Kobayashi H, Boelte KC, Lin PC (2007) Curr Med Chem 14(4): 377-86
    › Primary publication · 17305540 (PubMed)
  9. Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Kobayashi H, DeBusk LM, Babichev YO, Dumont DJ, Lin PC (2006) Blood 108(4): 1260-6
    › Primary publication · 16638932 (PubMed) · PMC1895873 (PubMed Central)
  10. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC (2005) Arthritis Rheum 52(5): 1585-94
    › Primary publication · 15880817 (PubMed)
  11. Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Kobayashi H, Lin PC (2005) Front Biosci : 666-74
    › Primary publication · 15569607 (PubMed)
  12. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Kobayashi H, Tan EM, Fleming SE (2004) Int J Cancer 109(2): 207-13
    › Primary publication · 14750171 (PubMed)
  13. Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells independently of p53 status. Kobayashi H, Tan EM, Fleming SE (2003) Nutr Cancer 46(2): 202-11
    › Primary publication · 14690797 (PubMed)